177Lu-iPSMA, whose clinical cases are reported in this research, is a new peptide ligand containing a pyridine ring and a hydrazine group that provides an additional anchoring site to target the PSMA enzyme and a molecular spatial configuration that favors its ability to remain in tumor lesions to produce ablative doses of radiation in a highly selective mode [9,10]. The gene discussed is FOLH1; the disease is neoplasm.